| Year |
Citation |
Score |
| 2023 |
Sheill G, Brady L, Hayes B, Baird AM, Guinan E, Vishwakarma R, Brophy C, Vlajnic T, Casey O, Murphy V, Greene J, Allott E, Hussey J, Cahill F, Van Hemelrijck M, ... ... Lynch T, et al. ExPeCT: a randomised trial examining the impact of exercise on quality of life in men with metastatic prostate cancer. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 31: 292. PMID 37086362 DOI: 10.1007/s00520-023-07740-4 |
0.339 |
|
| 2020 |
Brady L, Hayes B, Sheill G, Baird AM, Guinan E, Stanfill B, Vlajnic T, Casey O, Murphy V, Greene J, Allott EH, Hussey J, Cahill F, Van Hemelrijck M, Peat N, ... ... Lynch T, et al. Platelet cloaking of circulating tumour cells in patients with metastatic prostate cancer: Results from ExPeCT, a randomised controlled trial. Plos One. 15: e0243928. PMID 33338056 DOI: 10.1371/journal.pone.0243928 |
0.363 |
|
| 2017 |
Sheill G, Brady L, Guinan E, Hayes B, Casey O, Greene J, Vlajnic T, Cahill F, Van Hemelrijck M, Peat N, Rudman S, Hussey J, Cunningham M, Grogan L, Lynch T, et al. The ExPeCT (Examining Exercise, Prostate Cancer and Circulating Tumour Cells) trial: study protocol for a randomised controlled trial. Trials. 18: 456. PMID 28978344 DOI: 10.1186/s13063-017-2201-3 |
0.341 |
|
| 2016 |
Moloughney JG, Kim PK, Vega-Cotto NM, Wu CC, Zhang S, Adlam M, Lynch T, Chou PC, Rabinowitz JD, Werlen G, Jacinto E. mTORC2 Responds to Glutamine Catabolite Levels to Modulate the Hexosamine Biosynthesis Enzyme GFAT1. Molecular Cell. PMID 27570073 DOI: 10.1016/J.Molcel.2016.07.015 |
0.421 |
|
| 2016 |
Meunier A, Flores AN, McDermott N, Rivera-Figueroa K, Perry A, Lynch T, Redalen KR, Marignol L. Hypoxia regulates Notch-3 mRNA and receptor activation in prostate cancer cells. Heliyon. 2: e00104. PMID 27441277 DOI: 10.1016/j.heliyon.2016.e00104 |
0.398 |
|
| 2016 |
Jacinto E, Moloughney J, Kim PK, Vega-Cotto NM, Wu C, Lynch T, Zhang S, Adlam M, Guntaka S, Chou P, Rabinowitz JD, Werlen G. Abstract 21: The mTORC2 target Akt is regulated in response to glutamine metabolite levels Cancer Research. 76: 21-21. DOI: 10.1158/1538-7445.Am2016-21 |
0.492 |
|
| 2015 |
Jacinto E, Moloughney J, Lynch T, Wu C, Ibironke O, Navia A, Chou P, Zhang S, Rabinowitz J, Werlen G. Abstract 1150: mTORC2 enhances flux through the hexosamine biosynthetic pathway by regulation of GFAT1 expression Cancer Research. 75: 1150-1150. DOI: 10.1158/1538-7445.Am2015-1150 |
0.494 |
|
| 2014 |
Ferrer CM, Lynch TP, Sodi VL, Falcone JN, Schwab LP, Peacock DL, Vocadlo DJ, Seagroves TN, Reginato MJ. O-GlcNAcylation regulates cancer metabolism and survival stress signaling via regulation of the HIF-1 pathway. Molecular Cell. 54: 820-31. PMID 24857547 DOI: 10.1016/J.Molcel.2014.04.026 |
0.589 |
|
| 2014 |
Bolton EM, Tuzova AV, Walsh AL, Lynch T, Perry AS. Noncoding RNAs in prostate cancer: the long and the short of it. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 35-43. PMID 24146262 DOI: 10.1158/1078-0432.CCR-13-1989 |
0.357 |
|
| 2014 |
Wu C, Lynch T, Moloughney J, Navia A, Ibironke O, Chou P, Vega-Cotto NM, Zhang S, Rabinowitz J, Werlen G, Jacinto E. Abstract 2441: mTOR complex 2 modulates glycosylation of CD147 via the hexosamine biosynthetic pathway Cancer Research. 74: 2441-2441. DOI: 10.1158/1538-7445.Am2014-2441 |
0.445 |
|
| 2013 |
Marignol L, Rivera-Figueroa K, Lynch T, Hollywood D. Hypoxia, notch signalling, and prostate cancer. Nature Reviews. Urology. 10: 405-13. PMID 23712204 DOI: 10.1038/nrurol.2013.110 |
0.384 |
|
| 2013 |
O'Rourke CJ, Knabben V, Bolton E, Moran D, Lynch T, Hollywood D, Perry AS. Manipulating the epigenome for the treatment of urological malignancies. Pharmacology & Therapeutics. 138: 185-96. PMID 23353098 DOI: 10.1016/j.pharmthera.2013.01.007 |
0.359 |
|
| 2013 |
Perry AS, O'Hurley G, Raheem OA, Brennan K, Wong S, O'Grady A, Kennedy AM, Marignol L, Murphy TM, Sullivan L, Barrett C, Loftus B, Thornhill J, Hewitt SM, Lawler M, ... ... Lynch T, et al. Gene expression and epigenetic discovery screen reveal methylation of SFRP2 in prostate cancer. International Journal of Cancer. Journal International Du Cancer. 132: 1771-80. PMID 22915211 DOI: 10.1002/ijc.27798 |
0.355 |
|
| 2012 |
Sullivan L, Murphy TM, Barrett C, Loftus B, Thornhill J, Lawler M, Hollywood D, Lynch T, Perry AS. IGFBP7 promoter methylation and gene expression analysis in prostate cancer. The Journal of Urology. 188: 1354-60. PMID 22906661 DOI: 10.1016/j.juro.2012.06.002 |
0.379 |
|
| 2012 |
Lynch TP, Ferrer CM, Jackson SR, Shahriari KS, Vosseller K, Reginato MJ. Critical role of O-Linked β-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis. The Journal of Biological Chemistry. 287: 11070-81. PMID 22275356 DOI: 10.1074/Jbc.M111.302547 |
0.742 |
|
| 2011 |
Lynch TP, Reginato MJ. O-GlcNAc transferase: a sweet new cancer target. Cell Cycle (Georgetown, Tex.). 10: 1712-3. PMID 21519190 DOI: 10.4161/Cc.10.11.15561 |
0.767 |
|
| 2011 |
Murphy TM, Sullivan L, Lane C, O'Connor L, Barrett C, Hollywood D, Lynch T, Lawler M, Perry AS. In silico analysis and DHPLC screening strategy identifies novel apoptotic gene targets of aberrant promoter hypermethylation in prostate cancer. The Prostate. 71: 1-17. PMID 20564325 DOI: 10.1002/pros.21212 |
0.32 |
|
| 2011 |
Lynch TP, Jackson SR, Shahriari KS, Ferrer CM, Lazarus M, Walker S, Vosseller K, Reginato MJ. Abstract 1267: Metabolic sensor O-GlcNAc Transferase is a novel regulator of prostate cancer invasion and angiogenesis via regulation of FoxM1 Cancer Research. 71: 1267-1267. DOI: 10.1158/1538-7445.Am2011-1267 |
0.729 |
|
| 2010 |
Caldwell SA, Jackson SR, Shahriari KS, Lynch TP, Sethi G, Walker S, Vosseller K, Reginato MJ. Nutrient sensor O-GlcNAc transferase regulates breast cancer tumorigenesis through targeting of the oncogenic transcription factor FoxM1. Oncogene. 29: 2831-42. PMID 20190804 DOI: 10.1038/Onc.2010.41 |
0.801 |
|
| Show low-probability matches. |